Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Serological markers as predictors of the severity of gastric mucosal atrophy in autoimmune and <i>Helicobacter рylori</i>-associated gastritis].

Terapevticheskii arkhiv·2025
Same author

Comparative Assessment of Manual Segmentation of Cerebral Infarction Lesions in Experimental Animals Based on Magnetic Resonance Imaging Using Artificial Intelligence.

Bulletin of experimental biology and medicine·2025
Same author

[Possibilities of post-processing of multislice computed tomography results in non-invasive diagnosis of pancreatic fibrosis].

Terapevticheskii arkhiv·2024
Same author

Estimation of the Ischemic Lesion in the Experimental Stroke Studies Using Magnetic Resonance Imaging (Review).

Bulletin of experimental biology and medicine·2024
Same author

[Modern concept of differential diagnosis of colitis: from G.F. Lang to the present day. A review].

Terapevticheskii arkhiv·2023
Same author

[Clinical cases of microscopic colitis: Diagnosis and treatment issues. Case report].

Terapevticheskii arkhiv·2023

Related Experiment Video

Updated: Jun 18, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

[Drug (statine)-induced hepatitis].

L B Lazebnik, L A Zvenigorodskaia, S G Khomeriki

    Eksperimental'Naia I Klinicheskaia Gastroenterologiia = Experimental & Clinical Gastroenterology
    |November 26, 2009
    PubMed
    Summary

    This case study highlights statin-induced liver injury in patients with ischemic heart disease and nonalcoholic fatty liver disease. It stresses the importance of liver protectants and dual cholesterol inhibition to prevent adverse effects.

    Related Experiment Videos

    Last Updated: Jun 18, 2026

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    Area of Science:

    • Hepatology
    • Cardiology
    • Pharmacology

    Background:

    • Ischemic heart disease (IHD) and nonalcoholic fatty liver disease (NAFLD) are common comorbidities.
    • Statin therapy is a cornerstone for managing hyperlipidemia in IHD patients.
    • NAFLD poses challenges in managing cardiovascular risk and drug-induced liver injury.

    Observation:

    • A clinical case of medicinal hepatitis developed due to irrational statin use in an IHD patient with NAFLD and morbid obesity.
    • The patient experienced adverse effects attributed to statin treatment.
    • This observation underscores the vulnerability of patients with co-existing liver and heart conditions.

    Findings:

    • Irrational statin use can precipitate drug-induced liver injury, particularly in patients with NAFLD.
    • Liver protectants are crucial for mitigating potential side effects of hypolipidemic statin therapy.
    • Dual cholesterol inhibition strategies may offer advantages in managing lipid profiles and reducing hepatic risks.

    Implications:

    • Clinicians should exercise caution when prescribing statins to patients with IHD and NAFLD, especially those with morbid obesity.
    • Proactive use of hepatoprotective agents should be considered to prevent statin-associated liver damage.
    • Further research into the benefits of double cholesterol inhibition in this patient population is warranted.